DIRS.INFO The most relevant business & tech news

☆ Living drugs that reprogram patients’ immune cells show early promise against hard-to-treat brain tumors
▼ + stars: | 2024-03-13 | by ( Brenda Goodman | ) edition.cnn.com time to read: +10 min

Only 3% to 5% of people who are diagnosed with this type of brain tumor will be alive three years later. Now, an experimental therapy that reprograms a person’s own immune cells to attack these tumors is showing some exciting promise. Doctors first harvested immune fighters called T-cells from his blood and then genetically modified them in a lab so they’d recognize and bind to specific proteins on the surface of the brain tumor cells. After a single 10-milliliter infusion of about 10 million CAR-T cells, Fraser’s tumor began to shrink. Three-quarters of the participants had had their brain tumors come back at least twice.

Persons: ”, Otis Brawley, –, they’ll, ” Brawley, Tom Fraser, Brigham, Debbie Fraser, Fraser, He’s, Marcela Maus, ” Fraser, Maus, “, ” Maus, Christine Brown, ’ Brown, ” Brown, hasn’t, Brown, Dr, Donald O’Rourke, “ They’re, O’Rourke, ” O’Rourke, Sanjay Gupta, you’re, they’re, it’s Organizations: CNN, Johns Hopkins University, American Cancer Society, City of Hope Cancer Center, University of Pennsylvania, Massachusetts General, Mass, New England, of Medicine, Doctors, Mass General Cancer Center, Tv3, Cell Therapeutics Research, of, Nature, Penn, Excellence, University of Pennsylvania Perlman School of Medicine, CNN Health Locations: City, Duarte , California, Massachusetts, Rochester , New York, Boston, of Hope, Hope

☆ FDA staff reviewers raise concerns over BrainStorm Cell's ALS therapy
▼ + stars: | 2023-09-25 | by ( ) www.reuters.com time to read: +2 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. Brainstrom's therapy, NurOwn, is being reviewed for the treatment of ALS, also known as Lou Gehrig's Disease, which affects nerve cells in the brain and spinal cord. The FDA had in November last year refused to accept the application for the therapy after BrainStorm failed to meet the main goal in a late-stage study. Over the last one year, the FDA has given accelerated approvals to Amylyx Pharmaceuticals' (AMLX.O) drug Relyvrio and Biogen's (BIIB.O) Qalsody for treatment of ALS. A panel of external advisors to the FDA is set to vote on the effectiveness of the therapy in ALS patients on Wednesday.

Persons: Andrew Kelly, Lou Gehrig's Disease, Amylyx, Mariam Sunny, Leroy Leo, Krishna Chandra Organizations: Food and Drug Administration, FDA, REUTERS, U.S . Food, Drug, Cell Therapeutics, Amylyx Pharmaceuticals, ALS Association, Thomson Locations: White Oak , Maryland, U.S, Bengaluru

Search resuls for: "Cell Therapeutics"

2 mentions found